These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 32385732)
1. Quality by Design-Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®. Zhang E; Xie L; Qin P; Lu L; Xu Y; Gao W; Wang L; Xie MH; Jiang W; Liu S AAPS J; 2020 May; 22(3):69. PubMed ID: 32385732 [TBL] [Abstract][Full Text] [Related]
2. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®. Magnenat L; Palmese A; Fremaux C; D'Amici F; Terlizzese M; Rossi M; Chevalet L MAbs; 2017 Jan; 9(1):127-139. PubMed ID: 27854156 [TBL] [Abstract][Full Text] [Related]
3. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®. Jaffar-Aghaei M; Khanipour F; Maghsoudi A; Sarvestani R; Mohammadian M; Maleki M; Havasi F; Rahmani H; Karagah AH; Kazemali MR Eur J Pharm Sci; 2022 Jun; 173():106171. PubMed ID: 35378209 [TBL] [Abstract][Full Text] [Related]
4. Physicochemical and Functional Characterization of HS016, a Biosimilar of Adalimumab (Humira). Gao D; Nie L; Yuan J; Hu F; Wu Z; Lin Q; Wang H J Pharm Sci; 2022 Apr; 111(4):1142-1151. PubMed ID: 34863972 [TBL] [Abstract][Full Text] [Related]
5. Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira Lee JJ; Yang J; Lee C; Moon Y; Ahn S; Yang J Biologicals; 2019 Mar; 58():7-15. PubMed ID: 30744947 [TBL] [Abstract][Full Text] [Related]
6. Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab. Liu J; Eris T; Li C; Cao S; Kuhns S BioDrugs; 2016 Aug; 30(4):321-38. PubMed ID: 27461107 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab. Lee N; Lee JJ; Yang H; Baek S; Kim S; Kim S; Lee T; Song D; Park G MAbs; 2019 Jan; 11(1):129-144. PubMed ID: 30296198 [TBL] [Abstract][Full Text] [Related]
8. Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumab. Sivendran R; Ramírez J; Ramchandani M; Liu J Immunotherapy; 2018 Aug; 10(11):1011-1021. PubMed ID: 30071739 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study. Zhang H; Wu M; Sun J; Zhu X; Li C; Ding Y; Zhang X; Chai K; Li X Pharmacol Res Perspect; 2021 Apr; 9(2):e00733. PubMed ID: 33682358 [TBL] [Abstract][Full Text] [Related]
10. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab. Schreiber S; Yamamoto K; Muniz R; Iwura T Pharmacol Res Perspect; 2020 Jun; 8(3):e00604. PubMed ID: 32500668 [TBL] [Abstract][Full Text] [Related]
11. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira. McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743 [TBL] [Abstract][Full Text] [Related]
12. Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®). Kwon JC; Kwon OH; Jeong RU; Kim N; Song S; Choi I; Lee J; Horiuchi T Anim Cells Syst (Seoul); 2021; 25(3):182-194. PubMed ID: 34262661 [TBL] [Abstract][Full Text] [Related]
13. Modulation of high mannose levels in N-linked glycosylation through cell culture process conditions to increase antibody-dependent cell-mediated cytotoxicity activity for an antibody biosimilar. Rameez S; Gowtham YK; Nayar G; Mostafa SS Biotechnol Prog; 2021 Sep; 37(5):e3176. PubMed ID: 34021724 [TBL] [Abstract][Full Text] [Related]